...
首页> 外文期刊>Molecular therapy: the journal of the American Society of Gene Therapy >Physiological Correction of Pompe Disease by Systemic Delivery of Adeno-associated Virus Serotype 1 Vectors.
【24h】

Physiological Correction of Pompe Disease by Systemic Delivery of Adeno-associated Virus Serotype 1 Vectors.

机译:通过系统性递送腺伴随病毒血清型1载体对庞贝病的生理校正。

获取原文
获取原文并翻译 | 示例

摘要

Pompe disease is caused by a lack of functional lysosomal acid alpha-glucosidase (GAA) and can ultimately lead to fatal hypertrophic cardiomyopathy and respiratory insufficiency. Previously, we demonstrated the ability of recombinant adeno-associated virus serotype 1 (rAAV2/1) vector to restore the therapeutic levels of cardiac and diaphragmatic GAA enzymatic activity in vivo in a mouse model of Pompe disease. We have further characterized cardiac and respiratory function in rAAV2/1-treated animals 1 year post-treatment. Similar to the patient population, electrocardiogram measurements (P-R interval) are significantly shortened in the Pompe mouse model. In rAAV2/1-treated mice, we show a significant improvement in cardiac conductance with prolonged P-R intervals of 39.34+/-1.6 ms, as compared to untreated controls (35.58+/-0.57 ms) (P
机译:庞贝病是由于缺乏功能性溶酶体酸α-葡萄糖苷酶(GAA)引起的,最终可能导致致命的肥厚性心肌病和呼吸功能不全。以前,我们证明了在庞贝氏病小鼠模型中重组腺相关病毒血清型1(rAAV2 / 1)载体在体内恢复心脏和diaphragm肌GAA酶活性的治疗水平的能力。我们进一步表征了治疗1年后经rAAV2 / 1处理的动物的心脏和呼吸功能。与患者人群相似,在庞贝(Pompe)小鼠模型中,心电图测量值(P-R间隔)明显缩短。在rAAV2 / 1治疗的小鼠中,与未治疗的对照组(35.58 +/- 0.57 ms)相比,我们在延长39-34 +/- 1.6 ms的P-R间隔时显示出心脏电导率的显着改善(P

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号